Aviceda Therapeutics is advancing its plans for Phase 3 trials of AVD-104, an experimental treatment for geographic atrophy, despite its recent setback in a Phase 2b study. This mid-stage trial aimed to evaluate AVD-104 against Astellas’ Izervay, but the results did not meet the predefined endpoints for efficacy, raising concerns about the drug’s potential in a competitive market.
The failure of the Phase 2b study highlights the challenges faced by pharmaceutical companies in developing effective therapies for age-related macular degeneration, a condition affecting millions globally. The implications of this setback are significant, as it may affect investor confidence and the company’s strategic direction moving forward.
However, Aviceda remains optimistic about the upcoming Phase 3 trials, suggesting that they believe in the drug’s potential to demonstrate efficacy in a larger patient population. The outcome of these trials will be crucial not only for Aviceda’s future but also for the broader landscape of treatments for geographic atrophy.
Get started today with Solo access →
